Aptensio XR
Sponsors
Rhodes Pharmaceuticals, L.P.
Conditions
Attention Deficit Disorder With Hyperactivity
Phase 4
A 12-Month Open Label Safety Study of Aptensio XR® in Children Ages 4-5 Years Diagnosed With ADHD
NCT02677519
Start: 2016-09-30End: 2017-09-30Target: 120Updated: 2016-08-25
A Flexible-Dose Titration Study of Aptensio XR in Children Ages 4 to Under 6 Years Diagnosed With ADHD
CompletedNCT02683265
Start: 2016-04-25End: 2018-03-27Updated: 2023-02-21